Once‐daily dosing showed no clear difference in adverse event compared with conventional dosing (high certainty).
Once‐daily dosing showed no clear difference in serious adverse events compared with conventional dosing (moderate certainty).
It is very uncertain whether once‐daily dosing changes withdrawal due to adverse events compared with conventional dosing (very low certainty).
Once‐daily dosing showed no clear difference in exclusion/withdrawal after entry compared with conventional dosing (high certainty).
Oral 5‐aminosalicylic acid showed no clear difference in failure to maintain clinical or endoscopic remission compared with comparator 5‐aminosalicylic acid formulation (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Oral 5‐aminosalicylic acid showed no clear difference in adverse event compared with comparator 5‐aminosalicylic acid formulation (low certainty).
Oral 5‐aminosalicylic acid showed no clear difference in serious adverse events compared with comparator 5‐aminosalicylic acid formulation (low certainty).
It is very uncertain whether oral 5‐aminosalicylic acid changes withdrawal due to adverse events compared with comparator 5‐aminosalicylic acid formulation (very low certainty).
Oral 5‐aminosalicylic acid showed no clear difference in exclusion/withdrawal after entry compared with comparator 5‐aminosalicylic acid formulation (moderate certainty).
Oral 5‐aminosalicylic acid showed no clear difference in adverse events compared with placebo (moderate certainty).
Oral 5‐aminosalicylic acid showed no clear difference in serious adverse events compared with placebo (low certainty).
Oral 5‐aminosalicylic acid showed no clear difference in withdrawal due to adverse event compared with placebo (moderate certainty).
Oral 5‐aminosalicylic acid showed no clear difference in exclusion/withdrawal after entry compared with placebo (moderate certainty).
It is very uncertain whether ciprofloxacin changes clinical remission compared with metronidazole (very low certainty).
It is very uncertain whether metronidazole changes adverse events compared with budesonide enema (very low certainty).
It is very uncertain whether rifaximin changes clinical remission compared with placebo (very low certainty).
It is very uncertain whether rifaximin changes clinical improvement compared with placebo (very low certainty).
The review found no eligible studies for this question.